PTCT
PTC THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$68.97
+1.25%Year over year
Reported trailing growth
- Revenue
- -35.1%
- EBITDA
- -80.9%
- EBIT
- -82.2%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- -98.5%
Forward estimates
Based on analyst estimates
- Revenue
- +13.4%
- EBITDA
- +171.2%
- EPS
- +243.7%
Three-year CAGR
- Revenue
- +35.3%
- EBITDA
- +836.9%
- EBIT
- +383.1%
- Net income
- +287.9%
- EPS
- +281.4%
- Free cash flow
- +326.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026